Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Antihypertensive Drugs: Potassium-Sparing Diuretics01:28

Antihypertensive Drugs: Potassium-Sparing Diuretics

582
Liddle syndrome is a genetically inherited form of hypertension characterized by the overactivity of epithelial sodium channels in the nephron, the functional unit of the kidney. This heightened activity leads to increased sodium reabsorption and excessive excretion of potassium. To counteract this, potassium-sparing diuretics such as amiloride are used. They function by blocking these sodium channels, thereby reducing the influx of sodium into the epithelial cells and minimizing the loss of...
582
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

1.4K
Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
1.4K
Antihypertensive Drugs: Thiazide-Class Diuretics01:15

Antihypertensive Drugs: Thiazide-Class Diuretics

680
Thiazide diuretics are sulfonamide derivatives featuring a benzothiadiazine ring system in their molecular structure. Based on this structure, thiazide diuretics can be categorized into two groups: thiazide-type and thiazide-like diuretics. Thiazide-type diuretics, including hydrochlorothiazide and chlorothiazide, consist of a benzothiadiazine backbone with an attached sulfonamide group. Thiazide-like diuretics, such as chlorthalidone and indapamide, lack the thiazide ring but demonstrate...
680
Qualitative Analysis03:46

Qualitative Analysis

22.4K
For solutions containing mixtures of different cations, the identity of each cation can be determined by qualitative analysis. This technique involves a series of selective precipitations with different chemical reagents, each reaction producing a characteristic precipitate for a specific group of cations. Metal ions within a group are further separated by varying the pH, heating the mixture to redissolve a precipitate, or adding other reagents to form complex ions.
For instance, group IV...
22.4K
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

1.0K
Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of...
1.0K
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

186
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
186

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Bisphosphonates: AHFS 92:24.

Journal of pain and symptom management·2019
Same author

Denosumab: AHFS 92:24.

Journal of pain and symptom management·2018
Same author

Guest editorial.

European journal of cancer care·2006
Same author

Assisted Dying for the Terminally Ill Bill, 2004.

Clinical medicine (London, England)·2005

Related Experiment Video

Updated: Jul 9, 2025

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5
09:46

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5

Published on: August 25, 2016

11.7K

Sodium zirconium cyclosilicate for hyperkalaemia.

Aafreen Shaikh1, Claire Stark Toller2

  • 1Mountbatten Hampshire, Southampton, UK.

BMJ Supportive & Palliative Care
|December 5, 2023
PubMed
Summary
This summary is machine-generated.

Hyperkalaemia, a serious condition, can now be managed non-invasively in hospices. Oral sodium zirconium cyclosilicate offered a palatable option, potentially improving quality of life for patients.

Keywords:
CancerHospice careTerminal care

More Related Videos

Patch Clamp Recordings in Inner Ear Hair Cells Isolated from Zebrafish
12:43

Patch Clamp Recordings in Inner Ear Hair Cells Isolated from Zebrafish

Published on: October 17, 2012

16.8K
Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.2K

Related Experiment Videos

Last Updated: Jul 9, 2025

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5
09:46

Adsorption Device Based on a Langatate Crystal Microbalance for High Temperature High Pressure Gas Adsorption in Zeolite H-ZSM-5

Published on: August 25, 2016

11.7K
Patch Clamp Recordings in Inner Ear Hair Cells Isolated from Zebrafish
12:43

Patch Clamp Recordings in Inner Ear Hair Cells Isolated from Zebrafish

Published on: October 17, 2012

16.8K
Generation of Local CA1 γ Oscillations by Tetanic Stimulation
08:02

Generation of Local CA1 γ Oscillations by Tetanic Stimulation

Published on: August 14, 2015

9.2K

Area of Science:

  • Palliative Care
  • Nephrology
  • Internal Medicine

Background:

  • Hyperkalaemia is a critical medical emergency requiring hospitalization.
  • Current treatments are often unsuitable for hospice patients.
  • There's a need for effective, non-invasive hyperkalaemia management in palliative care settings.

Purpose of the Study:

  • To report a case of oral sodium zirconium cyclosilicate use in a hospice inpatient with hyperkalaemia.
  • To assess the tolerability and potential efficacy of this treatment in a palliative care setting.

Main Methods:

  • A single hospice inpatient with hyperkalaemia was treated with oral sodium zirconium cyclosilicate.
  • The treatment was administered non-invasively.
  • Patient tolerance and clinical outcomes were monitored.

Main Results:

  • Oral sodium zirconium cyclosilicate was well tolerated by the patient.
  • The treatment may have contributed to an extended period of good quality of life (two weeks).
  • This non-invasive approach demonstrated feasibility in a hospice environment.

Conclusions:

  • Oral sodium zirconium cyclosilicate represents a potential non-invasive treatment option for hyperkalaemia in hospice care.
  • This case highlights the possibility of improving quality of life for palliative care patients with hyperkalaemia.
  • Further research is warranted to confirm the efficacy and safety of this approach in similar settings.